CrI 0.34-1.22); a statistically significantly improved PFS compared with erlotinib (HR 0.45, 95% CrI 0.22-0.90) and gefitinib (HR 0.51, 95% CrI 0.39-0.66); a trend towards improved PFS for afatinib (HR 0.67, 95% CrI 0.44-1.02), osimertinib (HR 0.93, 95% CrI 0.64-1.35) and icotinib (HR 0.59, 95% CrI 0.31-1.14). Conclusions: Overall, this NMA found that dacomitinib had a consistent trend towards improved OS and PFS when compared with other TKIs for first-line treating locally advanced or metastatic EGFR mutation positive NSCLC among Asian populations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.